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Recent data have indicated that the myocardium may act as an immune organ
initiating cardiac innate immune response and inflammation. It has been suggested that
activation of the immune system occurs upon the interaction of damage-associated
molecular patterns (DAMPs) generated and released during ischemic damage with pattern
recognition receptors (Toll like receptors; TLR) present in cardiac cells. Among TLRs, TLR4,
and TLR2 are the ones mostly expressed in cardiac tissue. Whereas TLR4 has shown to
play a detrimental role in myocardial ischemia/reperfusion (I/R) injury, the effect elicited by
TLR2 activation remains controversial. Once activated, TLR signaling may occur via the
Myd88- and Trif- dependent pathways leading to NFκB and IFN-3 activation, respectively,
and subsequent stimulation of pro-inflammatory and immunomodulatory cytokine gene
expression. Cytokine release contributes to neutrophils activation, recruitment, adhesion
and infiltration to the site of cardiac injury further perpetuating the inflammatory process.
This mini-review will focus on the current knowledge regarding the role of the heart in
inducing and coordinating the innate inflammatory response via the TLR signaling pathway
in myocardial I/R injury.
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ACTIVATION OF MYOCARDIAL TLR IN
ISCHEMIA/REPERFUSION
Activation of the innate immunity is an essential compo-
nent of the acute inflammatory response in the setting of
ischemia/reperfusion (I/R). It is widely recognized the key role
of neutrophils, monocytes, macrophages and dendritic cells in
innate immunity. However, recent experimental lines of evidence
have suggested that ischemic cardiomyocytes can also contribute
to the innate immune response besides being a target organ.
Activation of the immune response mainly occurs when “dan-
ger” signals released from the damaged cardiomyocytes [the so
called damage-associated molecular patterns (DAMPs)] interact
with pattern recognition receptors (PRRs). Among PRRs, Toll-
Like Receptors (TLR), originally identified 20 years ago for its
role in the embryonic development of the fruit fly Drosophila
melanogaster (Anderson et al., 1985), have been later recognized
as a key elements of the immune system (Lemaitre et al., 1996).
Ten TLR have been identified so far in humans six of which
are located in the cell surface and are activated by a variety
of exogenous/endogenous ligands (TLR1, TLR 2, TLR4, TLR5,
TLR6, and TLR10) and four are expressed intracellularly (TLR3,
TLR7, TLR8, and TLR9) and are generally recognized by nucleic
acid structures (Wang et al., 2010; Mann, 2011). Almost all cells
of the heart have shown to express TLR (TLR 2, 3, 4, and 6
are found in cardiomyocytes, and TLR1 through 6 are found in
the smooth muscle and endothelial cells) (Frantz et al., 2007).
The discovery of the notably contribution of TLR2 and TLR4 in
the development of atherosclerotic lesions and vascular remodel-
ing (Kiechl et al., 2002; Lin et al., 2009) and their abundance in
adult human hearts (Lin and Knowlton, 2014) frosted the inter-
est in deciphering their potential role in the setting of myocardial
I/R (Frantz et al., 1999). Although the mechanisms involved in
TLR 2 and 4 activation in myocardial I/R remain to be fully
described, a variety of endogenous molecules have been identified
to act as potential endogenous DAMPS. In one hand, myocar-
dial cell necrosis triggered during ischemia results in the release
of necrotic products and cellular constituents such as heat shock
proteins (HSP) and nuclear DNA-binding protein high mobil-
ity group box (HMGB-1) capable of activating the TLR2 and
TLR4 signaling. Dynamic alterations of extra cellular matrix
(ECM) resulting from I/R have also shown to generate DAMPs
molecules. In this regard, either breakdown products of the
cardiac ECM or de novo synthesized matrix molecules may func-
tion as endogenous ligands (Lin and Knowlton, 2014). Reactive
oxygen species have also demonstrated to activate cytokine pro-
duction through TLR4-dependent mechanisms, although the
molecules involved remain unknown (Flohe et al., 1997; Ha et al.,
2011). Finally, physical alterations of the receptor-plasma mem-
brane environment are thought to activate TLRs in the absence
of any cellular-/ECM-derived ligand (Figure 1) (Scaffidi et al.,
2002; Scheibner et al., 2006). Once activated, signal transduc-
tion of TLR2 and/or 4 may take place via two main pathways,
the Myd88- and TRIF- dependent pathway, eventually leading to
cytokine production.
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FIGURE 1 | Cardiac TLR2/4 structure, endogenous ligands and
signaling. This figure depicts the endogenous ligands released upon
ischemia and reperfusion that trigger signaling pathways activated by the
two most important cardiac TLR receptors, TLR2 and TLR4 and TLR
structure. HMGB, high mobility group box; HSP, heat-shock protein; HSCP,
heat shock cognate protein. LRR, extracellular C-terminal leucine-rich
repeat (ligand recognition domain); TIR-domain, N-terminal cytoplasmic
toll/interleukin receptor homologous signaling domain; IRAK, interleukin -1
receptor-associated kinase; TRAF6, tumor necrosis
factor-receptor-associated factor-6; TAK1, TGF-β-Activated Kinase-1; TAB1,
TAK1-Binding Protein-1; TAB2, TAK1-Binding Protein-2; UBC13,
ubiquitin-conjugating enzyme-13; UEV1A, ubiquitin-conjugating enzyme
E2-variant-1; IKK, Inhibitor of κ Light Polypeptide Gene Enhancer in
B-Cells Kinase; NF-κB, nuclear transcription factor- κB; MKK,
mitogen-activated protein kinase; TRIF, TIR domain-containing adaptor
protein inducing type 1 interferons; TRAM, Trif-related adaptor molecule;
TBK1, TANK Binding Kinase-1; IRF, interferon regulatory factor. AP-1,
transcription factor complex-1.
TLR SIGNAL TRANSDUCTION
TLR are type-I transmembrane proteins composed of 3 struc-
tural domains: an extracellular C-terminal leucine-rich repeat
(LRR) as ligand recognition domain, a central transmembrane
domain, and a cytoplasmic domain similar to the IL-1 receptor
(the toll/IL-1 receptor; TIR). Whereas TLR4 acts as homodimer,
TLR2 forms heterodimers with TLR1 and TLR6 (Wang et al.,
2010). TLR dimerization leads to changes in the conformation
of the cytoplasmic TIR domain which subsequently facilitates the
recruitment of adaptors that initiate TLRs downstream signal-
ing. Depending on the usage of different adaptor molecules, TLRs
signaling if divided in two major pathways, a MyD88-dependent
pathway and a TRIF-dependent pathway.
MyD88-DEPENDENT PATHWAY
Myd88 adaptor protein requires the recruitment of a TIR
domain-containing adaptor protein (TIRAP/Mal) to initiate
TLR4/2-related signaling. As shown in Figure 1 once stimu-
lated, the MyD88/TIRAP complex recruits and activates the
downstream interleukin -1 receptor-associated kinase 4 (IRAK4)
which induces IRAK1 phosphorylation and in turn recruits
TNF-Receptor-Associated Factor-6 (TRAF6) by associating with
phosphorylated IRAK1. Hereafter, phosphorylated TRAF6 then
dissociates from the receptor and forms a complex with the linker
molecules transforming growth factor β-activated kinase (TAK)-
1, TAK1-Binding Protein-1 (TAB1) and TAB2. TRAF6, TAK1,
TAB1, and TAB2 associate with the Ubiquitin ligases UBC13
Frontiers in Physiology | Cardiac Electrophysiology December 2014 | Volume 5 | Article 496 | 2
Vilahur and Badimon Myocardial TLR in ischemia/reperfusion
(Ubiquitin-Conjugating Enzyme-13) and UEV1A (Ubiquitin-
conjugating Enzyme E2-Variant-1). TAK1 is then activated
and phosphorylates the IKK complex (Inhibitor of κ Light
Polypeptide Gene Enhancer in B-Cells Kinase; IKK-α, IKK-β, and
IKK-γ) and p38 Kinases by activating MKK3 (Mitogen-Activated
Protein Kinase Kinase-3), MKK6 and MKK7. The IKK complex
then phosphorylates I-κB which leads to its ubiquitylation and
subsequent degradation. This allows NF-κB to translocate to the
nucleus which brings about the production of pro-inflammatory
cytokines and expression of co-stimulatory molecules (Ha et al.,
2011). On the other hand, p38 Kinases activates c-Jun Kinase
(JNKs) which then enter the nucleus and activates the transcrip-
tion factor complex (AP1) which also stimulates the expression of
pro-inflammatory cytokine genes (Figure 1) (Chao, 2009).
TRIF-DEPENDENT PATHWAY
TLR4 can also signal through a TRIF-dependent pathway
(also known as the MyD88-independent pathway; Figure 1).
In the TRIF-dependent pathway TLR4 may signal via TRIF-
related adaptor molecule (TRAM) and TRIF which activates
TBK1 (TANK Binding Kinase-1) eventually activating interferon-
regulatory factor-3 (IRF3). This pathway may also signal through
NF-κB signaling through TRAF6 recruitment. Activation of the
TRIF-dependent pathway induces IFNβ and IFN-inducible genes
including a variety of cytokines (Figure 1) (Chao, 2009).
All TLRs exert their action through the Myd88-dependent
pathway except for TLR3 and partially for TLR4 which exert
their action through the TRIF-dependent pathway. In fact, TRIF-
knock-out mice has shown impaired cytokine production despite
IRAK-1 phosphorylation and NF-κB activation suggesting that
TLR4 requires both Myd88- and TRIF-dependent pathways to
exert its action.
MYOCARDIAL TLR4 A NEW PLAYER IN I/R INJURY
Oyama et al. were the first to report a detrimental role for TLR4
in myocardial I/R injury (Oyama et al., 2004). Since then, sev-
eral investigations have corroborated that TLR4 deficient mice
show suppressed inflammatory response (lower NF-κB activation
and reduced TNFα and IL1β levels), decreased cardiac inflam-
matory infiltration and smaller infarctions as compared with
their wild-type littermates (Chong et al., 2004; Oyama et al.,
2004). Moreover, administration of a specific TLR4 antagonist
has shown to decrease NF-κB activation and subsequent pro-
inflammatory cytokine release limiting the size of infarction as
compared to non-treated animals (Kim et al., 2007a). However,
inconsistent results have been reported regarding the role of TLR4
in cardiac recovery after I/R, some studies showing improvement
(Kim et al., 2007b) and others no effect (Fallach et al., 2010).
A short-period of coronary ischemia (5min) has not shown
to trigger an inflammatory reaction (Bolli and Marban, 1999).
On the contrary, brief ischemic periods implemented before an
ischemic insult have shown to confer protection against pro-
longed ischemia (i.e., ischemic pre-conditioning) (Murry et al.,
1986). However, sustained ischemia has shown to result in a detri-
mental inflammatory response. In this regard, we have reported
in a preclinical model of closed-chest coronary balloon occlu-
sion that 30min of ischemia suffice to enhance the inflammatory
potential of circulating leukocytes and increase cytokines release
(Vilahur et al., 2009). Interestingly, such systemic inflammatory
response was associated with a marked upregulation of both
myocardial TLR-4- MyD88 -dependent and -TRIF-dependent
signaling pathways in the ischemic myocardium leading to NF-κB
nucleus translocation and IRF3 activation, respectively (Vilahur
et al., 2011). These observations support a relatively prompt
activation of the cardiac innate immune response upon an
ischemic insult that rapidly translates into a pro-inflammatory
systemic response through TLR4/cytokine networks. In addition,
these data also suggests that timely interception of TLR4 might
be critical to prevent adverse myocardial remodeling post-I/R
(Vilahur et al., 2011). Once activated, myocardial TLR4-related
inflammatory response stimulates the homing and recruitment
of neutrophils to the site of cardiac injury (Oyama et al.,
2004). Neutrophils recruitment and further infiltration may then
contribute to the detected raise in cardiac TLR-4 expression
detected up to 1 week after reperfusion (Vilahur et al., 2011).
Although the relative role of neutrophils TLR4 and myocar-
dial TLR4 in I/R-induced neutrophils cardiac infiltration has yet
to be clearly defined, an interesting study in Langendorff per-
fused heart supported that functional TLR4 in the myocardium
is required for neutrophils infiltration after global I/R. Besides,
it has been suggested that myocardial TLR4 mediates cardiac
chemokine response through a mechanisms involving HSC70,
released during ischemia (Ao et al., 2009). Neutrophils are the
major leukocytes found in I/R injury and not only are tar-
get cells for the cytokines released by the ischemic-reperfused
myocardium but also contribute to the progression of I/R tissue
damage. Released pro-inflammatory cytokines from the ischemic
reperfusedmyocardium activates both neutrophils and cardiomy-
ocytes leading to MAC-1 and intercellular adhesion molecule-
1 (ICAM1) expression, respectively. MAC-1/ICAM1 interaction
favors neutrophils adherence to cardiomyocytes which, in turn,
accelerates and perpetuates tissue injury via reactive oxygen
species (ROS) generation and pro-inflammatory cytokine release
by both cell types triggering a positive feedback loop (Arslan et al.,
2008).
THE CONTROVERSIAL ROLE OF TLR2 IN MYOCARDIAL I/R
INJURY
The role of myocardial TLR2 in the setting of I/R has been
poorly investigated. In fact, it still remains uncertain whether
it has a detrimental role in I/R injury similar to that of TLR4
or exerts beneficial effects. Shishido et al. (2003) reported that
infarct size and the degree of inflammatory cell infiltration in
the infarcted area were similar between wild type and TLR-2
knock-out mice. However, longer time-period analysis (up to 4
weeks) revealed that TLR-2 deficient mice showed lower fibrosis
in the non-infarcted myocardium and improved left-ventricular
remodeling parameters, as assessed by echocardiography, sug-
gesting a key role for TLR2 in the tissue repair process after
reperfusion (i.e., remodeling phase). Yet, it is unknown the rel-
ative contribution of TLR2 expressing inflammatory cells and
myocardial-related TLR2 in myocardial I/R injury. On the other
hand, studies in isolated hearts and infarcted mice have shown,
by using specific synthetic TLR2 ligands, that TLR2 is required
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for ischemic pre-conditioning-induced left ventricle functional
improvement and infarct size reduction and cardiac recovery,
respectively (Dong et al., 2010; Mersmann et al., 2010).
CONCLUDING REMARKS
Innate immunity triggers the initial inflammatory response upon
myocardial ischemia in part by the TLR signaling. Several lines of
evidence suggest the active involvement of the heart in inducing
and regulating the innate inflammatory response in the progres-
sion of myocardial I/R injury. Cardiacmyocytes exhibit properties
associated with the innate immune response, they are able to gen-
erate DAMPs and express TLRs. Although the mechanisms by
which TLRs exert their detrimental cardiovascular effects in the
setting of I/R are incompletely understood, during the last years
emerging evidence has indicated that cardiac TLR4 contribute to
cytokine release and neutrophils activation and recruitment to the
site of injury (Aikawa et al., 2001). In contrast, the role of TLR2
still remains unclear. Further research is needed to explore the
pathways and mechanisms by which the cardiac innate response
is activated following tissue injury. Development of selective
compounds capable to inhibit the TLR signaling may provide
important insights in this regard. Yet, it is important to consider
that although excessive pro-inflammatory cytokine production
exerts myocardial detrimental effects in the ischemic reperfused
myocardium, cytokines also drive the tissue repair process within
the heart.
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